Evaluation of Mycoplasma Inactivation during Production of Biologics: Egg-Based Viral Vaccines as a Model
- 1 May 2010
- journal article
- Published by American Society for Microbiology in Applied and Environmental Microbiology
- Vol. 76 (9) , 2718-2728
Abstract
Although mycoplasmas are generally considered to be harmless commensals, some mycoplasma species are able to cause infections in pediatric, geriatric, or immunocompromised patients. Thus, accidental contamination of biologics with mycoplasmas represents a potential risk for the health of individuals who receive cell-derived biological and pharmaceutical products. To assess the efficiency of inactivation of mycoplasmas by the agents used in the manufacture of egg-derived influenza vaccines, we carried out a series of experiments aimed at monitoring the viability of mycoplasmas spiked into both chicken allantoic fluid and protein-rich microbiological media and then treated with beta-propiolactone, formalin, cetyltrimethylammonium bromide, Triton X-100, and sodium deoxycholate, which are agents that are commonly used for virus inactivation and disruption of viral particles during influenza vaccine production. Twenty-two mycoplasma species (with one to four strains of each species) were exposed to these inactivating agents at different concentrations. The most efficient inactivation of the mycoplasmas evaluated was observed with either 0.5% Triton X-100 or 0.5% sodium deoxycholate. Cetyltrimethylammonium bromide at concentrations of ≥0.08% was also able to rapidly inactivate (in less than 30 min) all mycoplasmas tested. In contrast, negligible reductions in mycoplasma titers were observed with 0.0125 to 0.025% formaldehyde. However, increasing the concentration of formaldehyde to 0.1 to 0.2% improved the mycoplasmacidal effect. Incubation of mycoplasmas with 0.1% beta-propiolactone for 1 to 24 h had a marked mycoplasmacidal effect. A comparison of the mycoplasma inactivation profiles showed that strains of selected species ( M ycoplasma synoviae , M ycoplasma gallisepticum , M ycoplasma orale , M ycoplasma pneumoniae , and A choleplasma laidlawii ) represent a set of strains that can be utilized to validate the effectiveness of mycoplasma clearance obtained by inactivation and viral purification processes used for the manufacture of an inactivated egg-based vaccine.Keywords
This publication has 55 references indexed in Scilit:
- HPLC-based quantification of haemagglutinin in the production of egg- and MDCK cell-derived influenza virus seasonal and pandemic vaccinesVaccine, 2009
- Biological Enrichment of Mycoplasma Agents by Cocultivation with Permissive Cell CulturesApplied and Environmental Microbiology, 2008
- Time-Dependent Recovery of Mycoplasma lipofaciens (Strain ML64) from Incubated Infertile Chicken Eggs and Dead in Shell Chicken EmbryosAvian Diseases, 2008
- Inactivated infectious haematopoietic necrosis virus (IHNV) vaccinesJournal of Fish Diseases, 2008
- AvianMycoplasma lipofaciensTransmission to VeterinarianEmerging Infectious Diseases, 2008
- Post-operative mediastinitis, pleuritis and pericarditis due to Mycoplasma hominis and Ureaplasma urealyticum with a fatal outcomeJournal of Medical Microbiology, 2008
- Acute Polyarthritis and Septicemia from Mycoplasma edwardii after Surgical Removal of Bilateral Adrenal Tumors in a DogJournal of Veterinary Internal Medicine, 2005
- Investigations into the survival of Mycoplasma gallisepticum, Mycoplasma synoviae and Mycoplasma iowae on materials found in the poultry house environmentAvian Pathology, 1994
- ISOLATION OF MYCOPLASMA GALLISEPTICUM FROM EMBRYONATED CHICKEN EGGSAustralian Veterinary Journal, 1972
- A Study of the Properties of Eaton's Primary Atypical Pneumonia OrganismJournal of General Microbiology, 1962